HD-OPM Archive

How to read medical research: the hierarchy of evidence

Learn how the group's admins rank randomized trials, prospective cohorts, Mendelian randomization, meta-analyses and weaker study designs, and how to spot confounding, reverse causality and misleading citations.

16 min read44 group posts cited50 studies discussed3 chartsEvidence through Oct 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • Randomized controlled trials can establish causality, but most statin trials run only about 5 years, so long-term questions need prospective cohorts (which can run 30 years) and genetic studies.
  • Case series, cross-sectional and ecological studies sit at the bottom of the hierarchy and are mainly used to generate hypotheses, not to settle clinical questions.
  • Observational links such as 46% fewer cardiac events with shingles vaccination or about 90% higher odds of heart failure with melatonin can be produced by confounding or reverse causality.
  • Mendelian randomization works best for traits that genes directly control, such as LDL, and poorly for choices such as drinking alcohol.
  • A meta-analysis is only as good as the studies pooled: the 14% lower dementia risk with statins came from observational studies, not trials.
  • Before trusting a headline, ask where the study sits on the hierarchy, whether the outcome is a hard endpoint or a marker, and whether other studies agree.
In this summary
  1. Why study design matters
  2. The main study designs
  3. Common traps when reading headlines
  4. Where the admins' views differ or evidence is mixed
  5. What this means for you
  6. Frequently asked questions
  7. The evidence behind this summary

When a new study makes headlines, the most useful first question is not "what did it find?" but "what kind of study is it?" The group's admins, especially Louis Nervegna, repeatedly make this point: the design of a study determines what it can and cannot prove, and weak designs are often used to argue against strong ones.12

In the admins' view, randomized controlled trials (RCTs) and long prospective cohort studies sit at the top of the evidence hierarchy in medicine, with RCTs able to prove causality and cohorts able to follow people for decades.1 Mendelian randomization (genetic studies) adds a third line of evidence about lifelong effects. Case series, cross-sectional surveys and ecological (country-level) comparisons sit near the bottom.345

This article explains each design in plain language, shows how the group has applied them to real questions about cholesterol, diet, supplements and drugs, and flags where the admins disagree or where the evidence is mixed. It is a summary of group discussion, not medical advice; the admins recommend discussing decisions with your own doctor.

~5 yearstypical length of a statin trial, too short to test lifelong effects67
52 yearsaverage lifelong exposure captured by Mendelian randomization studies of cholesterol8
46%fewer cardiac events after shingles vaccination in an observational study: an association, not proof9
87%disagreement between trials (I2) in a four-trial Mediterranean-diet meta-analysis10

Why study design matters

Most claims in health groups boil down to "study X found Y." But a study that finds an association is very different from one that shows a cause. Louis sums up the problem this way: observational studies can only show associations, and those associations are often created by confounding or reverse causality rather than a true causal effect.11

Two terms come up constantly:

  • Confounding means a third factor explains the link. For example, people who get a shingles vaccine may simply take better care of their health in general, which could lower their cardiovascular risk regardless of the vaccine.9 Gokhan Can raises a similar point about nutrition research: foods labeled "unhealthy" tend to be cheaper and more convenient, so their consumption may track with limited time, resources or access to fresh food, which independently affect health.13
  • Reverse causality means the outcome (or an early stage of it) changes the exposure, not the other way around. Gokhan's example is that people with insulin resistance might gravitate toward protein- and fat-rich foods, rather than those foods causing the problem.13

Because of these problems, the admins urge readers to ask one question first when someone posts a study: where does it fall on the hierarchy?214 Louis calls it a common technique to cite studies from the bottom of the hierarchy to try to refute studies at the top.12

The evidence pyramid the admins point to: randomized clinical studies at the top, then prospective and retrospective cohorts, case-control, cross-sectional and ecological studies, with case series and case reports at the bottom.
The evidence pyramid the admins point to: randomized clinical studies at the top, then prospective and retrospective cohorts, case-control, cross-sectional and ecological studies, with case series and case reports at the bottom.14

The main study designs

Randomized controlled trials (RCTs)

In an RCT, participants are assigned by chance to an intervention or a control, which balances known and unknown differences between groups. That is why Louis describes large, long-running RCTs as the highest quality evidence and the only design that can directly prove causality.1015

Examples the group relies on:

  • A May 2024 meta-analysis of the four large Mediterranean-diet RCTs (Lyon Diet Heart Study, Indo-Mediterranean Diet Heart Study, PREDIMED and CORDIOPREV; 10,054 participants, average age 57, follow-up of 2 to 7 years) found lower rates of major cardiovascular events against control diets similar to American Heart Association recommendations of the time.10
  • Six randomized diet trials have shown plaque reversal (Lifestyle Heart, STARS, SCRIP, PREDIMED, CORDIOPREV and DISCO), all primarily plant-based but none strictly vegan.15
  • Every large randomized trial of HDL-raising drugs failed to reduce heart attacks and strokes, which Louis uses to show why a marker that tracks with risk is not automatically a target.1216

RCTs have limits. Louis notes that statin RCTs usually last about 5 years and that it is impractical to run RCTs much longer than that.67 They also test one intervention in one population, so the result depends on who was enrolled and for how long.

Prospective cohort studies

A prospective cohort study follows a group of people forward in time and records what happens. Louis explains that these studies track people continuously over time before they develop disease, and that they can run for decades.15 The Framingham Heart Study is the example Louis gives of a prospective cohort that produced some of the most reliable knowledge in cardiology.7

The trade-off is that cohorts cannot show causality on their own. Louis puts it plainly: they run much longer than RCTs, but they cannot prove cause.17 He therefore argues that a combination is best: RCTs for causality, prospective cohorts for the long term.1

Mendelian randomization (MR)

MR uses genetic variants, which are assigned at conception, as a natural experiment. Posts in the group describe it as nature running randomized trials over a lifetime: people who inherit variants that lower LDL stay at lower LDL for life, and their rates of heart disease are compared with those who do not.1819

What the group takes from MR:

  • A chart from a European Atherosclerosis Society consensus statement shows that variants acting through different pathways (LDLR, PCSK9, APOB, HMGCR, NPC1L1, SORT1, ABCG5/8) change coronary risk in proportion to how much they change LDL, the same linear relationship seen in statin trials.18
  • Louis combines RCTs, cohorts and MR in one graph: a 39 mg/dL LDL reduction was associated with over 20% lower heart attack risk at 5 years (RCTs), over 30% at 12 years (cohorts) and over 50% at 52 years (MR).620 The extension to absolute lifetime risk is Louis's own extrapolation.6
  • MR studies track lifelong exposure, which helps explain findings that short trials miss. A million-person MR study found that statin-like (HMGCR) and ezetimibe-like (NPC1L1) variants were linked to 76% and 82% lower dementia risk per roughly 40 mg/dL drop in non-HDL cholesterol, whereas PCSK9-related variants showed no benefit.1921 Short RCTs, by contrast, show no cognitive harm or benefit.21
  • MR can also challenge observational links. A 2024 MR study found no association between genetically predicted VO2-max and longevity or diabetes, even though VO2-max is linked to lower mortality in observational studies; Louis reads this as reverse causality or confounding.22
The Mendelian randomization chart shared in the group: each dot is a gene variant (LDLR, PCSK9, APOB, HMGCR, NPC1L1, SORT1, ABCG5/8 and others), plotted by how much it changes LDL and how much it changes coronary heart disease risk. The variants fall close to a single straight line.
The Mendelian randomization chart shared in the group: each dot is a gene variant (LDLR, PCSK9, APOB, HMGCR, NPC1L1, SORT1, ABCG5/8 and others), plotted by how much it changes LDL and how much it changes coronary heart disease risk. The variants fall close to a single straight line.18

Limits of MR. Louis stresses that MR is fundamentally observational: it can hint at causality, generally better than other observational designs, but only RCTs can definitively prove it.23 It works well for things genes directly control, such as LDL or familial hypercholesterolemia, and poorly for behaviors like drinking alcohol, because no gene forces someone to drink, and variants such as ALDH2 can alter other behaviors and cluster in certain ethnic groups.23 He also notes that MR gives a lifetime average and cannot distinguish moderate daily drinking from binge drinking.23

Meta-analyses

A meta-analysis pools the results of many studies. The key lesson from the group is to look at what was pooled.

  • Meta-analyses of RCTs are strong. A Cholesterol Treatment Trialists' analysis of 27 statin RCTs found similar proportional reductions in major vascular events per 1 mmol/L LDL reduction in women (rate ratio 0.84) and men (0.78).24 Meta-analyses of statin RCTs also found no effect on cancer incidence or mortality: odds ratio 0.99 in a 2023 analysis of 35 trials, and relative risk 0.97 in a 2017 analysis of 21 trials.1725
  • Meta-analyses of observational studies inherit the weaknesses of their parts. Statin use was associated with 20% lower dementia risk across 36 studies (OR 0.80) and 32% lower Alzheimer's risk across 21 studies; the authors called for dedicated randomized trials.26 A later analysis of 55 studies and about 7 million people reported 14% lower all-cause dementia, but Louis corrected the sharing account that called these clinical trials: they were cohort and case-control studies.27 He still finds the large pooled size compelling.27
  • Dose-response cohort meta-analyses estimate trends. A 17-cohort analysis of 896,871 people linked each daily yogurt serving to about 7% lower all-cause and 14% lower cardiovascular mortality, with most benefit at about 0.5 servings per day; it shows association, not causation.28
  • Meta-analyses can show nothing or harm. A review of 884 supplement RCTs found benefits for omega-3, folic acid and CoQ10 but no effect of vitamins C, D, E or selenium on cardiovascular disease, and beta-carotene increased all-cause mortality (RR 1.10).29
In 884 supplement trials, some helped and one harmedRelative risk versus placebo or control, selected results from a meta-analysis of randomized trials of micronutrient supplements
interval clear of 195% confidence interval
Omega-3: cardiovascular death0.93 (0.88–0.97)
Omega-3: heart attack0.85 (0.78–0.92)
Folic acid: stroke0.84 (0.72–0.97)
CoQ10: death from any cause0.68 (0.49–0.94)
*Beta-carotene: death from any cause1.10 (1.05–1.15)
Vitamins C, D, E and selenium showed no effect on cardiovascular disease. Different supplements and outcomes; each row is a separate pooled estimate. Source: 29
Show data
Relative risk (log scale)95% CI
Omega-3: cardiovascular death0.930.88–0.97
Omega-3: heart attack0.850.78–0.92
Folic acid: stroke0.840.72–0.97
CoQ10: death from any cause0.680.49–0.94
*Beta-carotene: death from any cause1.101.05–1.15
The statin-dementia signal comes from observational studiesPercent lower dementia risk in statin users versus non-users, in two meta-analyses of observational (cohort and case-control) studies
All dementia, 36 studies (OR 0.80)20%
Alzheimer's, 21 studies32%
All-cause dementia, 55 studies, about 7 million people14%
Alzheimer's, same 55-study analysis18%
Neither analysis pooled randomized trials; the authors of the first called for dedicated trials, and short statin RCTs show no cognitive harm or benefit. Source: 212627
Show data
Value
All dementia, 36 studies (OR 0.80)20%
Alzheimer's, 21 studies32%
All-cause dementia, 55 studies, about 7 million people14%
Alzheimer's, same 55-study analysis18%

Inside meta-analyses, check consistency. In the four-trial Mediterranean-diet analysis, the I2 statistic (a measure of how much trials disagree) was 87% for the composite of major cardiovascular events, and the reductions in all-cause mortality (OR 0.77) and revascularization did not reach statistical significance.10 A headline such as "48% fewer events" hides these details.30

Case series, cross-sectional and ecological studies

Louis places these designs at the bottom of the hierarchy.

  • Case series. He describes Esselstyn's published results as case-based observational studies in heavily medicated patients, mostly on statins, with no randomized trial of the diet.3
  • Cross-sectional studies. A study that looks at one snapshot in time is useful at best for generating hypotheses, as with an NHANES analysis of ketogenic diets of 43,776 adults.5
  • Ecological studies. A country-level analysis linking higher sodium intake with longer life expectancy shows that the country lives longer as a whole, not that individuals who eat more salt live longer, which Louis calls the ecological fallacy.4 He argues these are for hypothesis generation only and should not be lumped together with prospective cohorts.4

In short, as the group describes them:

DesignWhat it can showMain limitsExample from the group
Randomized controlled trialCause and effect1015Usually about 5 years; one intervention in one population67Four Mediterranean-diet RCTs, 10,054 participants10
Prospective cohortAssociations over decades15Cannot prove cause on its own17Framingham Heart Study7
Mendelian randomizationLifelong effects of traits genes control, such as LDL1823Observational; poor for behaviors such as drinking23Statin-like and ezetimibe-like variants and dementia19
Meta-analysisA pooled estimate across studiesOnly as strong as what was pooled; check consistency102727 statin RCTs, women and men24
Case series, cross-sectional, ecologicalHypotheses45No individual cause and effect; ecological fallacy4Esselstyn's case series, an NHANES keto snapshot, country-level sodium345

Common traps when reading headlines

U-shaped curves and reverse causality

Observational data often show higher mortality at both low and high LDL. Louis points out that similar U-shapes appear for BMI, A1C and blood pressure, where illness itself pushes the number down: cancer lowers LDL and BMI, liver and kidney disease lower A1C, and uncontrolled diabetes lowers blood pressure.31 For cancer, Louis cites a Circulation review: cholesterol falls faster before a cancer is diagnosed, statin RCTs show no increase in cancer, and MR (average 52 years of exposure) finds no extra cancer in people with genetically lower cholesterol.8 A 2022 cohort of about 36,500 people in China found that a U-shaped ApoB-mortality curve became linear after adjusting for comorbidities, bilirubin and malnutrition.32

The same cohort, before and after adjustment
Unadjusted: the hazard of death by ApoB level is U-shaped, with higher risk at low ApoB (figure A of the 2022 study).
Unadjusted: the hazard of death by ApoB level is U-shaped, with higher risk at low ApoB (figure A of the 2022 study).32
Adjusted for comorbidities, bilirubin and malnutrition: risk rises steadily with ApoB (figure D).
Adjusted for comorbidities, bilirubin and malnutrition: risk rises steadily with ApoB (figure D).32

Big relative numbers from observational data

Several posts show how dramatic percentages can mislead:

  • A shingles-vaccine study reported 46% fewer major cardiac events and 66% fewer deaths within a year in over 246,000 people with atherosclerotic heart disease, but Louis stresses it shows association, not causation.9
  • Long-term melatonin use was linked to about 90% higher odds of heart failure in over 130,000 adults with insomnia; Louis notes this is retrospective and could reflect confounding or reverse causality.33
  • A new Swedish cohort linked full-fat cheese and cream (but not low-fat versions, butter or milk) to lower dementia risk. Louis urges caution: it is the first such report, and the longer, larger Harvard Nurses Study has not reported it.11
  • In an Israeli observational study, risks reported for women starting hormone therapy at ages 50 to 65 (cancer +749%, stroke +1,569%) were larger than for those starting after 65, which an oncologist cited by Louis called implausible and a reason one study should not override decades of better evidence.34

Observational analyses of RCTs

Louis warns that influencers sometimes cite an RCT when they are really citing an ad hoc observational (post hoc) analysis done after the trial ended. He says such analyses cannot prove causality and must be weighed against all observational research.35 He applies the same caveat to the finding that PREDIMED nut eaters had about 40% lower total and cancer mortality in under 5 years, noting it "can't prove causality, but it can strongly hint at it."36

The metformin dementia analysis shows both sides. An observational follow-up of the Diabetes Prevention Program trial and its follow-up study reported over 50% lower dementia risk with metformin; it benefits from initial randomization, but after 3.2 years the study became open-label and many in the former placebo group later received metformin, blurring the comparison, and the finding is not conclusive.37

Surrogate markers versus hard outcomes

Many meta-analyses measure risk markers rather than events. Oats lowered LDL by 0.29 mmol/L across 74 RCTs, but apoB did not change significantly, based on only 2 studies.38 A berberine meta-analysis of 18 RCTs found small reductions in LDL, triglycerides and ApoB, and the authors called for trials with clinical outcomes.39 Statins lowered hs-CRP by about 1 mg/L across 26 RCTs.40 The HDL story is the cautionary tale: higher HDL tracks with lower risk in observational data, yet HDL-raising drugs have failed, and genes raising HDL do not lower lifetime risk.1216

Where the admins' views differ or evidence is mixed

  • How much to trust epidemiology. Gokhan argues that observational nutrition studies can be distorted by reverse causation and socioeconomic confounding and that intervention trials resolve this.13 Louis trusts prospective cohorts highly, ranking them at the top alongside RCTs.1 The two are not opposites, but emphasis differs.
  • Do you need RCTs at all? Louis argues that reliable knowledge does not require long RCTs: no human RCT showed that smoking causes lung cancer or that trans fats cause heart disease. Causality was established by combining prospective cohorts, short-term biomarker RCTs and animal mechanism studies, judged with Bradford-Hill criteria.7 Yet his personal rule is to not bet his life on anything not proven in multiple high-quality RCTs, and to add less-proven measures on top of standard care.41
  • Conflicting evidence on the same question. On ACE inhibitors versus ARBs, a 2012 meta-analysis of 20 RCTs reported lower all-cause mortality with ACE inhibitors (HR 0.90) but not ARBs (HR 0.99), nine head-to-head RCTs found no difference (RR 0.98), and a target trial emulation reported higher mortality with ACE inhibitors (HR 1.13). The post concludes the question remains genuinely unsettled.42
  • Time horizon. Short trials may understate benefits that build over decades, so MR and cohort results can differ from RCTs without either being wrong.619
ACE inhibitors versus ARBs: one interval excluded 1, the other did notHazard ratio for death from any cause versus control, 2012 meta-analysis of 20 RCTs in about 159,000 people with high blood pressure
interval clear of 1interval includes 1 (no clear difference)95% confidence interval
ACE inhibitors0.90 (0.84–0.97)
ARBs0.99 (0.94–1.04)
Nine head-to-head RCTs found no difference between the classes (RR 0.98), and a target trial emulation reported higher mortality with ACE inhibitors (HR 1.13); the question remains unsettled. Source: 42
Show data
Hazard ratio (log scale)95% CI
ACE inhibitors0.900.84–0.97
ARBs0.990.94–1.04

What this means for you

  • Identify the design first. Gokhan's lists tag each claim as [RCT] or [Association], a habit worth copying.43 The same list shows flu vaccination claims drawn from both RCTs and cohorts, with the post flagging observational limits.44
  • Treat observational headlines with big percentages as hypotheses, and look for replication.911
  • Prefer evidence from multiple high-quality RCTs for important decisions, as Louis does, and add less-proven measures on top of standard care, not instead of it.41
  • Check the age and the reference of what is cited. Louis says an influencer who can only cite studies from the 1960s and 1970s is ignoring 50 years of research, and that most people never look up cited references.35
  • Check whether the endpoint is a marker or a hard outcome such as heart attack, stroke or death.1239
  • Look at what a meta-analysis pooled, how consistent the trials were and which outcomes were not significant.1027
  • Be skeptical of MR for foods and drinks, and comfortable with it for biology genes control directly.1823
  • Discuss any treatment decision with your doctor.

Frequently asked questions

Does "observational" mean "wrong"?

No. Prospective cohorts are ranked at the top of the hierarchy by Louis and are the source of major cardiology knowledge, such as the Framingham Heart Study.17 The concern is the lower designs, and the fact that associations may reflect confounding or reverse causality.11

Is a meta-analysis always better than a single study?

Not automatically. A meta-analysis of RCTs is strong, but a meta-analysis of observational studies is still observational, as in the statin and dementia example.2627 Heterogeneity and non-significant outcomes also matter.10

Why do RCTs and genetic studies sometimes give different sizes of effect?

RCTs typically last about 5 years and start in late adulthood, while MR reflects lifelong exposure, so the effects can look much larger.619

Can Mendelian randomization prove cause and effect?

Louis says no: it is observational and only hints at causality, though more convincingly than ordinary observational studies, particularly for traits genes directly control.23

Why do people cite a study that seems to contradict an RCT?

Louis says it is a common tactic to cite low-tier studies, such as ecological or cross-sectional ones, to refute top-tier evidence, which is why he asks where the study falls on the hierarchy.245

The evidence behind this summary50 studies · 20 meta-analyses · 8 trials · 4 MR · 12 observational

The 44 group posts cited above discuss 50 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 20Randomized trials 8Mendelian randomization 4Observational studies 12Reviews & guidelines 6

Strongest evidence discussed

All 50 studies and sources
Sources from the group (44)
  1. Randomized trials and prospective cohorts top the evidence hierarchy Louis Nervegna · Sep 18, 2026 · Facebook
  2. Check where a study sits on the evidence hierarchy before citing it Louis Nervegna · Dec 10, 2023 · Facebook
  3. Esselstyn's diet evidence is case series, not RCTs; Mediterranean diet trials match it Louis Nervegna · Mar 07, 2025 · Facebook
  4. Why an ecological study on sodium and life expectancy is weak evidence Louis Nervegna · Aug 04, 2025 · Facebook
  5. Why a cross-sectional NHANES keto mortality study sits low on the evidence hierarchy Louis Nervegna · Jan 24, 2025 · Facebook
  6. LDL down 39 mg/dL: 20%+ fewer heart attacks in RCTs, 30%+ in cohorts, 50%+ genetically Louis Nervegna · Dec 20, 2023 · Facebook
  7. Reliable medical knowledge does not require RCTs: smoking and trans fats as examples Louis Nervegna · Jan 08, 2024 · Facebook
  8. Low LDL's link to cancer is reverse causality: cancer lowers cholesterol, not vice versa Louis Nervegna · Dec 21, 2023 · Facebook
  9. Shingles vaccine tied to 46% fewer major cardiac events in high-risk people Louis Nervegna · Mar 26, 2026 · Facebook
  10. Meta-analysis of 4 Mediterranean diet RCTs: MACE down 48%, CVD death down 46% Louis Nervegna · Jan 08, 2025 · Facebook
  11. Full-fat cheese and cream linked to lower dementia risk over 25 years (observational) Louis Nervegna · Dec 18, 2025 · Facebook
  12. HDL is a poor intervention target: every large HDL-raising trial has failed Louis Nervegna · Jul 28, 2025 · Facebook
  13. Why diet-health epidemiology may mislead: reverse causation and socioeconomic confounding Gokhan Can · Jan 15, 2025 · Facebook
  14. The hierarchy of evidence: don't refute top-tier studies with bottom-tier ones Louis Nervegna · Dec 31, 2024 · Facebook
  15. Six RCTs have shown diet can reverse plaque, and none used a purely vegan diet Louis Nervegna · Oct 24, 2025 · Facebook
  16. High HDL tracks with lower risk in UK Biobank, but HDL-raising drugs have failed Louis Nervegna · Oct 28, 2026 · Facebook
  17. Statin RCT meta-analyses show no increase or decrease in cancer risk Louis Nervegna · Dec 31, 2024 · Facebook
  18. Mendelian randomization: lifelong lower LDL tracks linearly with lower heart disease risk Louis Nervegna · Oct 10, 2026 · Facebook
  19. Statin- and ezetimibe-like gene variants linked to 76-82% lower dementia risk per 40 mg/dL Louis Nervegna · Aug 28, 2026 · Facebook
  20. A low-dose statin could roughly halve lifetime heart attack risk if taken for decades Louis Nervegna · Feb 25, 2025 · Facebook
  21. Mendelian randomization in 1 million people: statin-like genetics cut dementia risk 76-82% Gokhan Can · Nov 06, 2025 · Facebook
  22. Mendelian randomization finds no causal effect of VO2-max on longevity or diabetes Louis Nervegna · Sep 02, 2025 · Facebook
  23. Mendelian randomization is a poor tool for studying alcohol and CVD Louis Nervegna · Nov 06, 2025 · Facebook
  24. Statins work as well in women as men: 27-trial CTT meta-analysis of 174,000 participants Louis Nervegna · Dec 19, 2023 · Facebook
  25. Statins neither cause nor cure cancer: meta-analyses of randomized trials show no effect Gokhan Can · Dec 31, 2024 · Facebook
  26. Statin use linked to 20% lower dementia and 32% lower Alzheimer's risk in meta-analysis Louis Nervegna · Oct 22, 2024 · Facebook
  27. Statin users had 14% lower dementia risk in a meta-analysis of 7 million people Louis Nervegna · Aug 05, 2026 · Facebook
  28. Each daily yogurt serving linked to 14% lower CVD mortality in a 17-cohort meta-analysis Gokhan Can · Feb 16, 2025 · Facebook
  29. Review of 884 supplement RCTs: omega-3, folic acid and CoQ10 helped; beta-carotene harmed Louis Nervegna · Nov 30, 2023 · Facebook
  30. Mediterranean-diet RCT meta-analysis: 48% fewer MACE; WFPBNO only has one small RCT Louis Nervegna · Jun 13, 2025 · Facebook
  31. U-shaped mortality curves for cholesterol, BMI, A1C and BP reflect reverse causality Louis Nervegna · May 11, 2025 · Facebook
  32. U-shaped ApoB-mortality curve turns linear after adjusting for bilirubin and malnutrition Louis Nervegna · Jun 01, 2024 · Facebook
  33. Long-term melatonin use linked to higher heart failure risk in an observational analysis Louis Nervegna · Nov 03, 2025 · Facebook
  34. Israeli HRT study's 749% higher cancer risk at ages 50-65 is implausible, says oncologist Louis Nervegna · Mar 19, 2026 · Facebook
  35. Influencers citing only 1960s-70s studies or post-hoc RCT analyses are likely misleading Louis Nervegna · Oct 23, 2025 · Facebook
  36. PREDIMED nut eaters had about 40% lower total and cancer mortality in under 5 years Louis Nervegna · Mar 03, 2026 · Facebook
  37. Metformin associated with over 50% lower dementia risk in 20-year DPP/DPPOS follow-up Louis Nervegna · Aug 25, 2026 · Facebook
  38. 74 RCTs show oats lower LDL, blood sugar, weight and waist circumference Louis Nervegna · Jun 24, 2025 · Facebook
  39. Berberine modestly lowers LDL, triglycerides and ApoB: meta-analysis of 18 RCTs Louis Nervegna · Sep 03, 2026 · Facebook
  40. Meta-analysis of 26 RCTs: statins lowered hs-CRP by about 1 mg/L in patients with CVD Louis Nervegna · Jul 12, 2024 · Facebook
  41. A rule for deciding: don't bet your life on anything not proven in high-quality RCTs Louis Nervegna · Oct 12, 2025 · Facebook
  42. ACE inhibitors cut all-cause mortality 10% in RCT meta-analysis; ARBs showed none Louis Nervegna · Apr 21, 2026 · Facebook
  43. Interventions that extended human longevity in RCTs: weight loss, vaccines and more Gokhan Can · Nov 18, 2023 · Facebook
  44. Flu vaccination and mortality: the author's reading of the evidence Gokhan Can · Nov 18, 2023 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary